Navigation Links
Valtech Cardio Ltd. Completes $17.8 Million in Series B Financing
Date:2/2/2010

OR YEHUDA, Israel, Feb. 2 /PRNewswire/ -- Valtech Cardio Ltd. announced today that new and existing investors (OXO Capital Valve Ventures LLC, NGN Biomed Opportunity II, L.P., and Peregrine VC Investments II, L.P.) recently completed a Series B financing of $17.8 million.

Valtech Cardio Ltd. (Valtech) is engaged in development of a portfolio of minimally-invasive surgical and transcatheter mitral valve repair and replacement technologies designed to correct or significantly improve mitral valve function in ways that reduce or eliminate mitral regurgitation (MR).  MR is a serious heart disorder characterized by incomplete closure of the mitral valve.  The valve leakage (from the left ventricle into the left atrium), often called regurgitation, reduces the amount of blood that is pumped out of the heart during each contraction and is associated with other serious medical conditions, including atrial fibrillation.  MR is believed to be the most common form of valvular heart disease.

"The enthusiastic support from our investor group provides us with the capital necessary to complete development and initial clinical evaluation of several products designed to dramatically improve mitral valve function," said Amir Gross, Founder and Chief Operating Officer of Valtech.  "The Valtech team is focused on improved annuloplasty and chordal repair technologies that will help physicians more effectively treat their patients undergoing surgical (open and minimally-invasive) and percutaneous transcatheter mitral valve repair procedures," Gross commented.

"The medical community has clearly articulated the need for advanced mitral valve repair and replacement solutions," said Lawrence C. Best, Executive Chairman of the Board.  "The mitral valve repair/replacement market appears to be primed for rapid adoption of advanced solutions that address the needs of patients and physicians.  Such product offerings should result in significant new growth opportunities in the coming years," Mr. Best added.

Valtech Cardio Ltd. is a privately held medical device company, based in Or Yehuda, Israel with a U.S. office in Waltham, Ma., committed to the development and commercialization of therapies for the millions of patients afflicted with mitral valve disorders.

SOURCE Valtech Cardio Ltd.


'/>"/>
SOURCE Valtech Cardio Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
2. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
3. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
4. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
7. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
8. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
9. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
10. Cardiologists Tackle Next Frontier in Cardiovascular Disease
11. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... Jun 27, 2017   NuEyes (NuEyes Technologies Inc.) ... to fuel its growth in helping the legally blind live ... Design Group), the leading developer of augmented, virtual and mixed ... The undisclosed funding amount was provided by strategic ... Angel, with offices in Abu Dhabi , ...
(Date:6/19/2017)... 19, 2017  Researchers from DRUGSCAN ® and ... host a live, complimentary webinar titled, "Untangling methods to ... the real world" on Wednesday June 28, 2017 from ... This webinar will feature interviews with recreational and dependent ... manipulation techniques abusers use to prepare opioid tablets for ...
(Date:6/14/2017)... 2017  ivWatch LLC, a medical device company focused ... therapy, is pleased to announce it was the Bronze ... Supplies and Equipment at the 2017 Medical Design Excellence ... industry. The award was presented by Medical Device and ... in New York during MD&M ...
Breaking Medicine Technology:
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... device compliance and commercialization, has just announced two more sessions of its “From ... engineering into risk management activities. Led by David Cronin, Cognition’s CEO, the half-hour ...
(Date:7/18/2017)... ... July 18, 2017 , ... The results of an international clinical trial, led in ... for a severe type of muscular dystrophy holds promise for a subgroup of patients. , ... McDonald and colleagues at 53 study sites in 18 countries describe the clinical benefit ...
(Date:7/18/2017)... ... July 18, 2017 , ... An inventor from Anacortes, ... "Due to menopause, I have frequent hot flashes, and I suffer from anxiety and ... way to keep cool while out and about." INSTA-FAN meets that need. , This ...
(Date:7/18/2017)... ... July 18, 2017 , ... Heritage Woods of Benton, a ... to 12:30 p.m. on Aug. 15. , The community, which is located at 1305 ... Medicaid, who need some help to maintain their independence. , The lunch menu will ...
(Date:7/18/2017)... ... 18, 2017 , ... FCPX LUT Berlin for Final Cut Pro X gives ... includes 60 different color-grade presets, giving FCPX users numerous options for adding different color ... each subject, plus much more. FCPX LUT Berlin is designed for any skill-level, from ...
Breaking Medicine News(10 mins):